EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development

Deepak Gupta, Pankaj K Singh, Pavan K Yadav, Tadigoppula Narender, Umesh K Patil, Sanjay K Jain, Manish K Chourasia

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2022.109649 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Deepak Gupta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar 470003, M.P., India; Division of Pharmaceutic…. Hauptthemen laut MEDLINE: Antiprotozoal Agents, Leishmaniasis, Visceral, Leishmania, Leishmaniasis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 258 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular therapy refers to targeted therapies based on molecules which have been intelligently directed towards specific biomolecular structures and include small molecule drugs, monoclonal antibodies, proteins and peptides, DNA or RNA-based strategies, targeted chemotherapy and nanomedicines. Molecular therapy is emerging as the most effective strategy to combat the present challenges of life-threatening visceral leishmaniasis, where the successful human vaccine is currently unavailable. Moreover, current chemotherapy-based strategies are associated with the issues of ineffective targeting, unavoidable toxicities, invasive therapies, prolonged treatment, high treatment costs and the development of drug-resistant strains. Thus, the rational approach to antileishmanial drug development primarily demands critical exploration and exploitation of biochemical differences between host and parasite biology, immunocharacteristics of parasite homing, and host-parasite interactions at the molecular/cellular level. Following this, the novel technology-based designing and development of host and/or parasite-targeted therapeutics having leishmanicidal and immunomodulatory activity is utmost essential to improve treatment efficacy. Thus, the present review is focused on immunological and molecular checkpoint targets in host-pathogen interaction, and molecular therapeutic prospects for Leishmania intervention, and the challenges ahead.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiprotozoal AgentsLeishmaniasis, VisceralLeishmaniaLeishmaniasisHumansDrug DevelopmentTreatment Outcome

Stichwörter der Autor:innen

Checkpoint targetsChemotherapyMolecular therapeuticsMolecular therapyNanomedicinesVisceral leishmaniasis

Substanzen

Antiprotozoal Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar 470003, M.P., India; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow…
  • Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad 5000…
  • Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.
  • Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.
  • Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar 470003, M.P., India.
  • Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India. Electronic address: manish_chourasia@cdri.res.in.

Zitieren

APA

Gupta, D., Singh, P. K., Yadav, P. K., Narender, T., Patil, U. K., Jain, S. K., & Chourasia, M. K. (2023). Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2022.109649

Vancouver

Gupta D, Singh PK, Yadav PK, Narender T, Patil UK, Jain SK, et al. Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2022.109649

BibTeX
@article{Gupta2023,
  author = {Gupta, Deepak and Singh, Pankaj K and Yadav, Pavan K and Narender, Tadigoppula and Patil, Umesh K and Jain, Sanjay K and Chourasia, Manish K},
  title = {Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2022.109649}
}
Kostenlos starten →